Bispezifische Antikörper: Hoffnungsträger in der Krebsimmuntherapie


Nearly seventy years have passed since the first attempts to fuse the antibodies, „magic bullets“ with exquisite target specificity, into multispecific agents that can connect a targeted cell with an effector
immune cell. Such efforts have triggered a plethora of engineering advancements to optimize the antigen engagement. Even the most conserved domains of the antibody molecule have been modified to achieve two unique chains pairing, or with an introduction of novel antigen binding sites.

Sollte Ihr Browser keine automatische Weiterleitung unterstützen, dann klicken Sie bitte hier, um das gewünschte PDF herunterzuladen.